Observational studyJMIR public health and surveillance2024
Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study.
Observational study in JMIR public health and surveillance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Rundong Qin *Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China, 86 189 2886 8259, 86 20 3429 8996.ORCID 0000-0001-8067-6307
Yan Feng *Department of Otolaryngology Head and Neck Surgery, The First Hospital, Shanxi Medical University, Taiyuan, China.ORCID 0000-0002-1443-0584
Huanping Zhang *Department of Allergology, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Shanxi, China.ORCID 0000-0003-2263-6774
Beibei Zhao *Department of Allergy, The Second Affiliated Hospital of Dalian Medical University, Liaoning, China.ORCID 0009-0000-1797-9831
Wei Lei *Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0001-8498-7161
Hongying Sun *Department of Pulmonary and Critical Care Medicine, The First Hospital of Jilin University, Changchun, China.ORCID 0009-0006-7707-6451
Lili Zhi *Department of Allergy, Shandong Provincial Qianfoshan Hospital, Shandong Institute of Respiratory Diseases, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.ORCID 0000-0001-5664-9974
Zhongsheng Zheng *Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.ORCID 0000-0002-2587-7680
Siqin Wang *Department of Allergy, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China.ORCID 0000-0003-3601-7827
Yafeng Yu *Department of Otolaryngology, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0003-3558-0263
Shengxue Jiang *Department of Allergy, Shengjing Hospital of China Medical University, Liaoning, China.ORCID 0009-0007-4803-6415
Changshan Liu *Department of Pediatrics, The Second Hospital of Tianjin Medical University, Children's Respiratory and Asthma Research Center of Tianjin Medical University, Tianjin, China.ORCID 0000-0002-1828-8204
Xingkai Ma *Department of Otorhinolaryngology, The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, China.ORCID 0000-0002-5337-8977
Hui Ma *Department of Respiratory and Critical Care Medicine, Chest Hospital, Tianjin University, Tianjin, China.ORCID 0000-0003-4854-6187
Huiying Wang *Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.ORCID 0000-0002-4855-4323
Hang Lin *Department of Allergy, The Affiliated Hospital of Qingdao University, Qingdao, China.ORCID 0009-0005-3122-6779
Qiaojie He *Department of Allergy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID 0009-0007-8060-9404
Lingying Wu *Department of Allergy, The Third People's Hospital of Datong, Datong, China.ORCID 0009-0005-2357-9785
Yingying Zhai *Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0001-9668-562X
Honglue Lu *Department of Otolaryngology, Suzhou Hospital, Affiliated Hospital of Medical School, Nanjing University, Suzhou, China.ORCID 0000-0002-0882-2311
Shi Chen *Center for Prevention and Treatment of Pediatric Asthma, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.ORCID 0009-0008-5061-0364
Yan Ma *Department of Otorhinolaryngology Head and Neck Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.ORCID 0000-0002-7684-7254
Xiaohong Jin *Department of Pediatrics, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, China.ORCID 0009-0003-9918-446X
Shan Deng *Department of Allergy, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID 0000-0002-9645-5397
Nanshan Zhong *Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.ORCID 0000-0003-2274-1427
Ruchong Chen *Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China, 86 189 2886 8259, 86 20 3429 8996.ORCID 0000-0001-5376-8230
Jing Li *Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China, 86 189 2886 8259, 86 20 3429 8996.ORCID 0000-0002-6459-7470
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Background: Allergic diseases are associated with an increased susceptibility to respiratory tract infections. Although allergen immunotherapy (AIT) alters the course of allergies, there is limited evidence from clinical practice demonstrating its ability to enhance the host defense against pathogens. Objective: The aim of this study was to investigate the protective effect of AIT against viral infection in patients with allergic rhinitis (AR) and allergic asthma (AS) based on clinical evidence. Methods: A multicenter, questionnaire-based survey was conducted during a tremendous surge in COVID-19 cases between February 10, 2023, and March 15, 2023, in 81 centers across China recruiting healthy volunteers and patients with AR and AS to investigate the clinical outcomes of COVID-19 infection. Results: Of 10,151 participants recruited in the survey, 3654 patients and 2192 healthy volunteers who tested positive for COVID-19 were included in this analysis after screening. Overall, no significant differences in COVID-19 outcomes were observed between patients and healthy volunteers. An additional 451 patients were excluded due to their use of biologics as the sole add-on treatment, leaving 3203 patients in the further analysis. Of them, 1752 were undergoing routine medication treatment (RMT; the RMT group), whereas 1057 and 394 were receiving AIT and a combination of AIT and omalizumab (OMA) as adjunct therapies to RMT, respectively (AIT+RMT and AIT+OMA+RMT groups). The AIT group showed milder COVID-19 symptoms, shorter recovery periods, and a lower likelihood of hospitalization or emergency department visits than the RMT group (all P<.05). After adjusting for confounding factors, including demographic characteristics and COVID-19 vaccination, AIT remained a significant protective factor associated with shorter recovery time (adjusted odds ratio [OR] 0.62, 95% CI 0.52-0.75; adjusted P<.001) and a lower incidence of hospitalization or emergency department visits (adjusted OR 0.73, 95% CI 0.54-0.98; adjusted P=.03). Furthermore, the AIT+OMA+RMT group showed greater protection with a shorter recovery time (adjusted OR 0.51, 95% CI 0.34-0.74; adjusted P<.001) than the AIT+RMT group. Conclusions: Our multicenter observational study provides valuable clinical evidence supporting the protective effect of AIT against COVID-19 infection in patients with AR and AS.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Protective Effect of Allergen Immunotherapy in Patients With Allergic Rhinitis and Asthma Against COVID-19 Infection: Observational, Nationwide, and Multicenter Study. · full record | OpenQuestion